Merck & Co., Inc. (MRK) PB Ratio: 6.51
Is Merck & Co., Inc.’s P/B ratio high or low?
Merck & Co., Inc.'s P/B ratio of 6.51 is in line with its 5-year average of 5.97, around the middle of its 5-year range (3.85–8.97).
30.63% above its 12-month average of 4.98.
MRK PB Ratio Chart
MRK Average PB Ratio Chart
MRK Current vs Average PB Ratio Chart
MRK PB Ratio Metrics
PB RATIO
6.51
PB RATIO AVG TTM
4.98
PB RATIO AVG 3Y
6.03
PB RATIO AVG 5Y
5.97
PB RATIO AVG 10Y
5.86
PB RATIO AVG 15Y
4.83
PB RATIO AVG 20Y
4.51
CURRENT VS TTM AVG
+30.63%
CURRENT VS 3Y AVG
+7.94%
CURRENT VS 5Y AVG
+8.99%
CURRENT VS 10Y AVG
+11.07%
CURRENT VS 15Y AVG
+34.68%
CURRENT VS 20Y AVG
+44.46%
MRK Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $298.23B | 6.51 | 4.98 | 6.03 | 5.97 |
| UnitedHealth Group Incorporated (UNH) | $369.16B | 3.56 | 3.06 | 4.63 | 5.31 |
| AbbVie Inc. (ABBV) | $399.86B | 14.59 | 147.05 | 61.32 | 40.26 |
| Amgen Inc. (AMGN) | $188.37B | 19.99 | 21.33 | 23.63 | 31.88 |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 3.41 | 3.75 | 4.21 | 4.73 |
| Gilead Sciences, Inc. (GILD) | $156.35B | 6.48 | 7.47 | 6.02 | 5.35 |
| Abbott Laboratories (ABT) | $155.75B | 3.00 | 4.07 | 4.66 | 5.09 |
| Pfizer Inc. (PFE) | $149.61B | 1.67 | 1.63 | 1.71 | 2.35 |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 8.48 | 10.30 | 10.61 | 9.88 |
| CVS Health Corporation (CVS) | $126.70B | 1.62 | 1.29 | 1.17 | 1.37 |
P/B vs. its own history
At 6.51, P/B is richer than usual, sitting higher than 83% of its 20-year history.
20-year low
1.15
median
4.23
20-year high
8.97
Book Value Analysis
P/B Ratio
6.51
Market Price / Book Value per Share
Merck & Co., Inc. PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. PB Ratio FAQ
- What is the P/B ratio for Merck & Co., Inc. (MRK)?
- The P/B ratio for MRK stock is 6.51.
- Is Merck & Co., Inc.'s P/B ratio high or low?
- Merck & Co., Inc.'s P/B ratio of 6.51 is in line with its 5-year average of 5.97, around the middle of its 5-year range (3.85–8.97).
- What is the TTM average P/B ratio for Merck & Co., Inc. (MRK)?
- The TTM average P/B ratio for MRK stock is 4.98.
- What is the 3Y average P/B ratio for Merck & Co., Inc. (MRK)?
- The 3Y average P/B ratio for MRK stock is 6.03.
- What is the 5Y average P/B ratio for Merck & Co., Inc. (MRK)?
- The 5Y average P/B ratio for MRK stock is 5.97.
- What is the 10Y average P/B ratio for Merck & Co., Inc. (MRK)?
- The 10Y average P/B ratio for MRK stock is 5.86.
- What is the 15Y average P/B ratio for Merck & Co., Inc. (MRK)?
- The 15Y average P/B ratio for MRK stock is 4.83.
- What is the 20Y average P/B ratio for Merck & Co., Inc. (MRK)?
- The 20Y average P/B ratio for MRK stock is 4.51.
Merck & Co., Inc. PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-11 | 6.51 |
| 2026-06-10 | 6.42 |
| 2026-06-09 | 6.44 |
| 2026-06-08 | 6.44 |
| 2026-06-05 | 6.51 |
| 2026-06-04 | 6.48 |
| 2026-06-03 | 6.18 |
| 2026-06-02 | 6.23 |
| 2026-06-01 | 6.21 |
| 2026-05-29 | 6.40 |
| 2026-05-28 | 6.46 |
| 2026-05-27 | 6.48 |
| 2026-05-26 | 6.45 |
| 2026-05-22 | 6.60 |
| 2026-05-21 | 6.24 |
| 2026-05-20 | 6.09 |
| 2026-05-19 | 6.16 |
| 2026-05-18 | 6.06 |
| 2026-05-15 | 6.00 |
| 2026-05-14 | 6.11 |
| 2026-05-13 | 6.11 |
| 2026-05-12 | 6.05 |
| 2026-05-11 | 6.00 |
| 2026-05-08 | 6.00 |
| 2026-05-07 | 6.05 |
| 2026-05-06 | 6.12 |
| 2026-05-05 | 6.10 |
| 2026-05-04 | 6.09 |
| 2026-05-01 | 5.30 |
| 2026-04-30 | 5.16 |
| 2026-04-29 | 5.25 |
| 2026-04-28 | 5.20 |
| 2026-04-27 | 5.21 |
| 2026-04-24 | 5.29 |
| 2026-04-23 | 5.42 |
| 2026-04-22 | 5.34 |
| 2026-04-21 | 5.32 |
| 2026-04-20 | 5.54 |
| 2026-04-17 | 5.63 |
| 2026-04-16 | 5.46 |
| 2026-04-15 | 5.58 |
| 2026-04-14 | 5.67 |
| 2026-04-13 | 5.68 |
| 2026-04-10 | 5.74 |
| 2026-04-09 | 5.80 |
| 2026-04-08 | 5.83 |
| 2026-04-07 | 5.64 |
| 2026-04-06 | 5.72 |
| 2026-04-02 | 5.72 |
| 2026-04-01 | 5.72 |
| 2026-03-31 | 5.69 |
| 2026-03-30 | 5.59 |
| 2026-03-27 | 5.66 |
| 2026-03-26 | 5.62 |
| 2026-03-25 | 5.65 |
| 2026-03-24 | 5.50 |
| 2026-03-23 | 5.47 |
| 2026-03-20 | 5.40 |
| 2026-03-19 | 5.40 |
| 2026-03-18 | 5.42 |
| 2026-03-17 | 5.48 |
| 2026-03-16 | 5.46 |
| 2026-03-13 | 5.47 |
| 2026-03-12 | 5.48 |
| 2026-03-11 | 5.50 |
| 2026-03-10 | 5.54 |
| 2026-03-09 | 5.54 |
| 2026-03-06 | 5.48 |
| 2026-03-05 | 5.49 |
| 2026-03-04 | 5.69 |
| 2026-03-03 | 5.67 |
| 2026-03-02 | 5.74 |
| 2026-02-27 | 5.86 |
| 2026-02-26 | 5.64 |
| 2026-02-25 | 5.79 |
| 2026-02-24 | 5.86 |
| 2026-02-23 | 5.97 |
| 2026-02-20 | 5.89 |
| 2026-02-19 | 5.87 |
| 2026-02-18 | 5.86 |
| 2026-02-17 | 5.86 |
| 2026-02-13 | 5.85 |
| 2026-02-12 | 5.74 |
| 2026-02-11 | 5.75 |
| 2026-02-10 | 5.64 |
| 2026-02-09 | 5.67 |
| 2026-02-06 | 5.87 |
| 2026-02-05 | 5.77 |
| 2026-02-04 | 5.70 |
| 2026-02-03 | 5.58 |
| 2026-02-02 | 5.46 |
| 2026-01-30 | 5.31 |
| 2026-01-29 | 5.22 |
| 2026-01-28 | 5.15 |
| 2026-01-27 | 5.20 |
| 2026-01-26 | 5.17 |
| 2026-01-23 | 5.21 |
| 2026-01-22 | 5.26 |
| 2026-01-21 | 5.35 |
| 2026-01-20 | 5.27 |
| 2026-01-16 | 5.24 |
| 2026-01-15 | 5.35 |
| 2026-01-14 | 5.35 |
| 2026-01-13 | 5.22 |
| 2026-01-12 | 5.26 |
| 2026-01-09 | 5.33 |
| 2026-01-08 | 5.35 |
| 2026-01-07 | 5.23 |
| 2026-01-06 | 5.25 |
| 2026-01-05 | 5.18 |
| 2026-01-02 | 5.13 |
| 2025-12-31 | 5.07 |
| 2025-12-30 | 5.11 |
| 2025-12-29 | 5.14 |
| 2025-12-26 | 5.14 |
| 2025-12-24 | 5.13 |
| 2025-12-23 | 5.06 |
| 2025-12-22 | 5.05 |
| 2025-12-19 | 4.87 |
| 2025-12-18 | 4.85 |
| 2025-12-17 | 4.78 |
| 2025-12-16 | 4.73 |
| 2025-12-15 | 4.83 |
| 2025-12-12 | 4.83 |
| 2025-12-11 | 4.77 |
| 2025-12-10 | 4.70 |
| 2025-12-09 | 4.67 |
| 2025-12-08 | 4.77 |
| 2025-12-05 | 4.80 |
| 2025-12-04 | 4.86 |
| 2025-12-03 | 4.93 |
| 2025-12-02 | 4.87 |
| 2025-12-01 | 4.91 |
| 2025-11-28 | 5.05 |
| 2025-11-26 | 5.04 |
| 2025-11-25 | 5.09 |
| 2025-11-24 | 4.84 |
| 2025-11-21 | 4.71 |
| 2025-11-20 | 4.58 |
| 2025-11-19 | 4.58 |
| 2025-11-18 | 4.65 |
| 2025-11-17 | 4.47 |
| 2025-11-14 | 4.48 |
| 2025-11-13 | 4.48 |
| 2025-11-12 | 4.41 |
| 2025-11-11 | 4.38 |
| 2025-11-10 | 4.18 |
| 2025-11-07 | 4.16 |
| 2025-11-06 | 4.13 |
| 2025-11-05 | 4.07 |
| 2025-11-04 | 4.30 |
| 2025-11-03 | 4.23 |
| 2025-10-31 | 4.41 |
| 2025-10-30 | 4.43 |
| 2025-10-29 | 4.44 |
| 2025-10-28 | 4.46 |
| 2025-10-27 | 4.51 |
| 2025-10-24 | 4.49 |
| 2025-10-23 | 4.47 |
| 2025-10-22 | 4.49 |
| 2025-10-21 | 4.49 |
| 2025-10-20 | 4.43 |
| 2025-10-17 | 4.35 |
| 2025-10-16 | 4.30 |
| 2025-10-15 | 4.31 |
| 2025-10-14 | 4.34 |
| 2025-10-13 | 4.40 |
| 2025-10-10 | 4.41 |
| 2025-10-09 | 4.49 |
| 2025-10-08 | 4.43 |
| 2025-10-07 | 4.49 |
| 2025-10-06 | 4.55 |
| 2025-10-03 | 4.57 |
| 2025-10-02 | 4.59 |
| 2025-10-01 | 4.62 |
| 2025-09-30 | 4.31 |
| 2025-09-29 | 4.03 |
| 2025-09-26 | 4.03 |
| 2025-09-25 | 3.98 |
| 2025-09-24 | 4.09 |
| 2025-09-23 | 4.10 |
| 2025-09-22 | 4.12 |
| 2025-09-19 | 4.18 |
| 2025-09-18 | 4.18 |
| 2025-09-17 | 4.16 |
| 2025-09-16 | 4.16 |
| 2025-09-15 | 4.16 |
| 2025-09-12 | 4.25 |
| 2025-09-11 | 4.37 |
| 2025-09-10 | 4.31 |
| 2025-09-09 | 4.34 |
| 2025-09-08 | 4.31 |
| 2025-09-05 | 4.35 |
| 2025-09-04 | 4.31 |
| 2025-09-03 | 4.32 |
| 2025-09-02 | 4.38 |
| 2025-08-29 | 4.31 |
| 2025-08-28 | 4.27 |
| 2025-08-27 | 4.31 |
| 2025-08-26 | 4.36 |
| 2025-08-25 | 4.38 |
| 2025-08-22 | 4.48 |
| 2025-08-21 | 4.42 |
| 2025-08-20 | 4.34 |
| 2025-08-19 | 4.36 |
| 2025-08-18 | 4.32 |
| 2025-08-15 | 4.32 |
| 2025-08-14 | 4.25 |
| 2025-08-13 | 4.24 |
| 2025-08-12 | 4.12 |
| 2025-08-11 | 4.10 |
| 2025-08-08 | 4.14 |
| 2025-08-07 | 4.12 |
| 2025-08-06 | 4.07 |
| 2025-08-05 | 4.14 |
| 2025-08-04 | 4.18 |
| 2025-08-01 | 4.15 |
| 2025-07-31 | 4.09 |
| 2025-07-30 | 4.28 |
| 2025-07-29 | 4.33 |
| 2025-07-28 | 4.40 |
| 2025-07-25 | 4.44 |
| 2025-07-24 | 4.40 |
| 2025-07-23 | 4.40 |
| 2025-07-22 | 4.27 |
| 2025-07-21 | 4.15 |
| 2025-07-18 | 4.19 |
| 2025-07-17 | 4.27 |
| 2025-07-16 | 4.32 |
| 2025-07-15 | 4.27 |
| 2025-07-14 | 4.38 |
| 2025-07-11 | 4.37 |
| 2025-07-10 | 4.40 |
| 2025-07-09 | 4.38 |
| 2025-07-08 | 4.26 |
| 2025-07-07 | 4.24 |
| 2025-07-03 | 4.24 |
| 2025-07-02 | 4.31 |
| 2025-07-01 | 4.28 |
| 2025-06-30 | 4.15 |
| 2025-06-27 | 4.14 |
| 2025-06-26 | 4.13 |
| 2025-06-25 | 4.17 |
| 2025-06-24 | 4.21 |
| 2025-06-23 | 4.20 |
| 2025-06-20 | 4.14 |
| 2025-06-18 | 4.15 |
| 2025-06-17 | 4.10 |
| 2025-06-16 | 4.24 |
| 2025-06-13 | 4.28 |
| 2025-06-12 | 4.28 |
| 2025-06-11 | 4.21 |
| 2025-06-10 | 4.26 |
| 2025-06-09 | 4.15 |
| 2025-06-06 | 4.14 |
| 2025-06-05 | 4.06 |
| 2025-06-04 | 4.10 |
| 2025-06-03 | 4.04 |
| 2025-06-02 | 3.99 |
| 2025-05-30 | 4.02 |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis